2020年6月17日

Respira 科技公司计划在2021年下半年向美国食品和药物管理局提交吸入器设备，以授权进行尼古丁替代疗法。

该公司的目标是破坏一个由制药公司以及烟草公司的电子尼古丁传送装置（具有将尼古丁转化成气雾剂的喷雾器）的数十年历史的口香糖和贴片所主导的6,180亿美元的市场。

总部位于美国加利福尼亚州西好莱坞的Respira表示，新冠Covid-19大流行引发了人们对戒烟的新兴趣，如今，使用蒸气装置和电子烟的用户需要更新的戒烟产品。

Respira首席执行官Mario Danek告诉Bloomberg科技，他说：“现实是，我们有对尼古丁成瘾的人，他们从未尝试过可燃产品。”他指的是像香烟和雪茄一样燃烧的烟草产品。

“他们习惯于藏匿产品，而我们拥有这种设计。”

Respira to Submit Nebulizer For FDA Approval

June 17, 2020

Respira Technologies plans to submit an inhaler device to the U.S. Food and Drug Administration by late 2021 for authorization as nicotine-replacement therapy.

The company aims to disrupt a $618 billion market dominated by decades-old gums and patches from pharmaceutical companies as well as tobacco companies’ electronic nicotine-delivery devices with a nebulizer that converts nicotine to an aerosol.

Based in West Hollywood, California, USA, Respira Technologies says that the Covid-19 pandemic has sparked new interest in quitting, and today’s users of vapor devices and e-cigarettes need updated cessation products.

“The reality is we have folks who are addicted to nicotine who never tried combustible products before,” Respira CEO Mario Danek told Bloomberg Technology, referring to tobacco products that are burned like cigarettes and cigars.

“They’re used to sleeker products, and we have that design.”